China lifts price caps on 1,500 drugs

05/11/2014 | Reuters

China's National Development and Reform Commission lowered from more than 2,000 to about 500 the number of drugs considered critical to health and subject to low-price caps. The commission noted that low prices have limited manufacturers' ability to absorb rising costs and caused shortages of some medicines. The commission has not announced the results of its yearlong investigation into the pricing practices of Chinese and international pharmaceutical firms.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park